Investigational drug · Phase 2
CVM-1118
Also called: TRX-818
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Advanced Cancer, Neuroendocrine Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "CVM-1118"
First trial start
2018
Dec 15, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CVM-1118", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Advanced Cancer
- Neuroendocrine Tumors
- Pancreatic Neuroendocrine Tumor
- Gastro-enteropancreatic Neuroendocrine Tumor
- Lung Neuroendocrine Neoplasm
- Neuroendocrine Carcinoma
Approved drugs for the same conditions: Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CVM-1118" as an intervention, largest first.
TaiRx, Inc.Industry
NCT05257590 · 95 participants (planned) · Start May 23, 2022 · Primary completion Dec 31, 2026
Drug: Nivolumab Injection [Opdivo]; CVM-1118 · For: Hepatocellular Carcinoma; Advanced Cancer
Sites: Kaohsiung City, Taiwan; Keelung, Taiwan; Tainan, Taiwan · 5 sites in all
- Study of CVM-1118 for Patients With Advanced Neuroendocrine TumorsActive, not recruiting
TaiRx, Inc.Industry
NCT03600233 · 34 participants · Start Dec 15, 2018 · Primary completion Sep 30, 2024
Drug: CVM-1118 · For: Neuroendocrine Tumors; Pancreatic Neuroendocrine Tumor; Gastro-enteropancreatic Neuroendocrine Tumor and 2 more
Sites: Kaohsiung City, Taiwan; New Taipei City, Taiwan; Taichung, Taiwan · 8 sites in all
TaiRx, Inc.Industry
NCT03582618 · 12 participants · Start Jul 12, 2018 · Primary completion Nov 16, 2021
Drug: Sorafenib; CVM-1118 · For: Hepatocellular Carcinoma; Advanced Cancer
Sites: Charleston, South Carolina; Tainan, Taiwan; Taipei, Taiwan
TaiRx, Inc.Industry
NCT04336124 · 5 participants · Start May 25, 2020 · Primary completion Feb 8, 2021
Drug: CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule) · For: Advanced Cancer
Sites: Taichung, Taiwan; Tainan, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
Yen CJ, Chen MH, Chen YY, et al. · Br J Cancer 2026
- Commentary: CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1.
Hendrix MJC, Seftor EA, Seftor REB, et al. · Pathol Oncol Res 2026
- Vascular mimicry in zebrafish fin regeneration: how macrophages build new blood vessels.
Senk A, Fazzari J, Djonov V · Angiogenesis 2024
- CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1.
Shen L, Chen YL, Huang CC, et al. · Pathol Oncol Res 2023
- Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.
Hendrix MJ, Seftor EA, Seftor RE, et al. · Pharmacol Ther 2016
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.